DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Sirukumab
Sirukumab
(COVID-19) in the Era of Cardiac Vigilance: a Systematic Review
As a Group, Anti- Inflammatories Will
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Tables-Of-Phase-3-Mabs.Pdf
The Two Tontti Tudiul Lui Hi Ha Unit
Plivensia, INN-Sirukumab
(INN) for Biological and Biotechnological Substances
13-400 Phrma Stateclinicaltrials MN 120913.Indd
WO 2018/234879 Al 27 December 2018 (27.12.2018) W !P O PCT
Biologicals in Rheumatoid Arthritis: Current and Future
Radiographic Progression in Clinical Trials in Rheumatoid Arthritis: a Systemic Literature Review of Trials Performed by Industry
INN Working Document 05.179 Update 2011
Standards, Perspektiven Und Grenzen Der Konservativen Therapie
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Sanofi's Sarilumab Bests Humira to Set up Arthritis Showdown
Safety of Synthetic and Biological Dmards: a Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations
(INN) for Biological and Biotechnological Substances
Anti-IL6R: Tocilizumab, Satralizumab, Sarilumab, Olokizumab, Vobarilizumab Anti-IL6: Siltuximab, Sirukumab, Clazakizumab
Top View
Long-Term Safety and Efficacy of Sirukumab for Patients with Rheumatoid Arthritis Who Previously Received Sirukumab in Randomise
WO 2018/013551 Al 18 January 2018 (18.01.2018) W !P O PCT
Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
944.1.Full.Pdf
FDA Briefing Document Arthritis Advisory Committee Meeting
Antibody Modeling
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Pipeline Trends December 2016
Bundled Contracts to Defend Against Biosimilars May Face Payer Skepticism
Spotlight on Sirukumab for the Treatment of Rheumatoid Arthritis: the Evidence to Date
Biological Agents for Giant Cell Arteritis: Treat to Target
Optumrx Brand Pipeline Forecast
Sirukumab for Rheumatoid Arthritis
WO 2013/087911 Al 20 June 2013 (20.06.2013) P O P C T
Sirukumab for Previously Treated Moderate to Severe Active Rheumatoid Arthritis
Translating IL-6 Biology Into Effective Treatments
Covid-19 and Patients Undergoing Pharmacological Treatments for Immune-Mediated Inflammatory Diseases: Protocol for a Rapid Living Systematic Review
Lack of Effect of 12-Week Treatment with Risankizumab on The
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland
Covid-19 and Patients Undergoing Pharmacological Treatments for Immune-Mediated Inflammatory Diseases: Protocol for a Rapid Living Systematic Review
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Highlights of FDA Activities – 7/1/17 – 7/31/17
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Earnings Presentation
(INN) for Biological and Biotechnological Substances
Effects of Immunomodulatory Drugs on Depressive Symptoms: a Mega-Analysis of Randomized, Placebo-Controlled Clinical Trials in Inflammatory Disorders
Investigating Sirukumab for Rheumatoid Arthritis: 2-Year Results from the Phase III SIRROUND-D Study
Antibodies[Version 1; Peer Review: 2 Approved]
Plivensia, INN-Sirukumab
Janssen Research & Development Briefing Document Arthritis Advisory
Cimzia (Certolizumab Pegol) (Rheumatoid Arthritis)
Compounds and Methods for Treating Inflammatory
Final Draft Late Stage Website Pipeline 2Q17 7.11.17
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
COVID-19 and Patients with Immune-Mediated Inflammatory
Jnj-Pipeline-4Q2016.Pdf
Quantify RA Clinical Outcomes Database
Antibodies to Watch in 2018